Latest News and Press Releases
Want to stay updated on the latest news?
-
MONTRÉAL, 03 nov. 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX : TH) (NASDAQ: THTX), une société biopharmaceutique axée sur le développement et la commercialisation...
-
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...
-
MONTRÉAL, 26 oct. 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX : TH) (NASDAQ : THTX), société biopharmaceutique axée sur le développement et la commercialisation de...
-
MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...
-
MONTREAL, Oct. 26, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), azienda biofarmaceutica focalizzata sullo sviluppo e la commercializzazione di...
-
MONTRÉAL, 22 oct. 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX : TH) (NASDAQ : THTX), une compagnie biopharmaceutique se spécialisant dans la commercialisation et le...
-
MONTREAL, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and...
-
– Les ventes consolidées du T3 2021 affichent une hausse de 27 % par rapport au T3 2020 – – La partie A du programme de phase 1 évaluant le TH1902 pour le traitement des cancers exprimant la...
-
- Q3 FY2021 consolidated sales grow 27% over Q3 FY2020 – - Ongoing Part A of Phase 1 program evaluating TH1902 for sortilin-expressing cancers indicating better tolerability than docetaxel alone – ...
-
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of...